Mayawala, Kapil
Merck & Co., Inc., Rahway, NJ, USA (United States)
3 papers on CoChatORCID 0000-0001-7959-4881
Most cited papers
- Verified
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
Lala, M., Li, T. R., de Alwis, D. P., Sinha, V., Mayawala, K., Yamamoto, N., Siu, L. L., Chartash, E., Aboshady, H., & Jain, L. (2020) · European Journal of Cancer
Cancer Immunotherapy and BiomarkersPharmaceutical studies and practices
Cited by 165
- Verified
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P. (2016) · Clinical Cancer Research
Statistical Methods in Clinical TrialsPharmaceutical studies and practices
Cited by 159
- Verified
Immunogenicity of pembrolizumab in patients with advanced tumors
van Vugt, M. J. H., Stone, J. A., De Greef, “. H. J. M. M., Snyder, E. S., Lipka, L., Turner, D. C., Chain, A., Lala, M., Li, M., Robey, S. H., et al. (2019) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersBiosimilars and Bioanalytical Methods
Cited by 57
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free